Neurocrine Biosciences Inc. Common Stock (NBIX)
Stock · NASDAQ · Health Care
$135.77as of 10/16/2026
Price chart
Active signals
Resistance level
$151.97
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
NBIX Signal Track Record
How signals performed across all stocks →What NBIX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +1.9% | 59% | September 18, 2026 |
| Bollinger Band Breakout | 28 | -0.1% | 50% | July 28, 2026 |
| Bollinger Band Breakdown | 19 | +0.7% | 58% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +4.1% | 75% | January 27, 2026 |
| Any 20-session window (baseline) | +1.6% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenit…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 2,500
- Website
- www.neurocrine.com/
Fundamentals
- 1-day range
- $135.55$138.23
- Market cap
- $16.25B
- P/E (trailing)
- 19.57
- P/E (forward)
- 11.46
- EPS (trailing)
- $6.82
- Dividend yield
- —
- Beta
- 0.34
- Avg. volume
- 1.32M
- Ex-dividend date
- December 29, 1995
52-week range
$122.14$186.12
Next earnings: November 2, 2026 · EPS estimate $2.72confirmed
How Neurocrine Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Gross Profit$2.81B(98%)
Operating Income$619.10M(22%)
Forecasts
29 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$253
+86.3%
Median
$213
+56.9%
Low
$150
+10.5%
Neurocrine Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NBIXNeurocrine Biosciences Inc. Common Stock$135.71▼ 0.91%Market cap $16.25BP/E 19.57$122.14$186.12
- EXELExelixis Inc. Common Stock$62.23▼ 0.95%Market cap $13.12BP/E 17.49$33.76$61.66
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 19.57 | $135.71 | ▼ 0.91% | $122.14$186.12 |
| EXEL Exelixis Inc. Common Stock | $13.12B | 17.49 | $62.23 | ▼ 0.95% | $33.76$61.66 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026benzinga · 10/16/2026
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayYahoo · 10/9/2026
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: Borg Warner, Boyd Gaming, JetBlue, Lattice Semiconductor, Lockheed Martin, Nike, Northrop Grumman, Procter & Gamble, SPX Technologies, and MoreYahoo · 10/6/2026
- Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207Benzinga · 10/6/2026
- Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value StockChartMill · 10/5/2026
- Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable ValuationChartMill · 10/2/2026
- Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family ConferenceYahoo · 9/30/2026
- UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214Benzinga · 9/29/2026
- Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical OfficerYahoo · 9/28/2026
Insider Activity
Insider Actions →Acquired
25.4K
Disposed
19.6K
- Matt Abernethy · September 14, 2026 · Sale2.3K @ $157.2
- David W. Boyer · September 14, 2026 · Sale826 @ $157.45
- Ingrid Delaet · September 11, 2026 · Tax Withholding2.4K @ $156.22
- Ingrid Delaet · September 11, 2026 · Grant4.5K
- David W. Boyer · September 11, 2026 · Tax Withholding1.9K @ $156.22
- David W. Boyer · September 11, 2026 · Grant3.6K
- BENEVICH ERIC · September 11, 2026 · Tax Withholding3.4K @ $156.22
- BENEVICH ERIC · September 11, 2026 · Grant6.3K
- Jude Onyia · September 11, 2026 · Tax Withholding1.9K @ $156.22
- Jude Onyia · September 11, 2026 · Grant3.6K
- Sanjay Chandru Keswani · September 11, 2026 · Tax Withholding2.1K @ $156.22
- Sanjay Chandru Keswani · September 11, 2026 · Grant3.9K
- Julie Cooke · September 11, 2026 · Tax Withholding1.9K @ $156.22
- Julie Cooke · September 11, 2026 · Grant3.6K
- Matt Abernethy · September 11, 2026 · Tax Withholding2.7K @ $156.22
Institutional Ownership
March 31, 2026
- Total shares held
- 89.06M
- Total value held
- $11.42B
- Institutional holders
- 680
Top holders this quarter
- Unknown13.39M
- Unknown5.46M
- Unknown4.94M
- Unknown4.51M
- Unknown4.35M
- Unknown3.06M
- Unknown2.42M
- Unknown2.14M
- Unknown1.49M
- Unknown1.39M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation
Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.